Investigational drug · Phase 3
mRNA-1018-H5
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "mRNA-1018-H5"
First trial start
2026
Mar 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "mRNA-1018-H5", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "mRNA-1018-H5" as an intervention, largest first.
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsPivotal-lookingActive, not recruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07496450 · 4,050 participants · Start Mar 23, 2026 · Primary completion Jan 28, 2027
Drug: mRNA-1018-H5; Placebo · For: Influenza
Sites: San Bernardino, California; Savannah, Georgia; Meridian, Idaho · 35 sites in all
- A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsPivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT05972174 · 1,504 participants · Start Jul 10, 2023 · Primary completion Jul 16, 2024
Drug: mRNA-1018 for H5N8; mRNA-1018 for H7N9 and 3 more · For: Influenza
Sites: Hollywood, Florida; Savannah, Georgia; Lenexa, Kansas · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- BRC-201TG-1000, Pixavir MarboxilPhase 31 trial
Boryung Biopharma Co., Ltd. · Influenza
- Fluzone QudrivalentPhase 22 trials
Sanofi · Healthy Volunteers, Influenza Immunization, Influenza
- TRX-100Phase 22 trials
Traws Pharma, Inc. · Influenza
- ApomivirFE-L-APO, drug substancePhase 21 trial
Far East Bio-Tec Co., Ltd · Influenza
- OVX836Phase 21 trial
Osivax · Influenza
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Moderna.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.